Learning Center
Plans & pricing Sign in
Sign Out

Breast Cancer Diagnostic and Drug Technologies: Global Markets


According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with breast cancer annually.

More Info
									Breast Cancer Diagnostic and Drug Technologies: Global
This BCC market research report provides a detailed overview and thorough analysis of the present and
future global market for breast cancer diagnostics and drug technologies. It provides detailed analysis of
the breast cancer drug and diagnostics markets, as well as the currently used personalized, predictive
and companion tests and their markets. The research also includes market characterization,
opportunities, the unmet needs associated with breast cancer, competitive assessment, product profiles
of major marketed products and promising drugs in the pipeline, an overview on discontinued projects,
implications for future market competition and the key players of the breast cancer market.

This report includes products in this market and detailed analyses of markets and competitive
environments. It also analyzes current and future market prospects. It provides a comprehensive review
of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to
companion tests, tumor markers and gene profiling assays relevant for breast cancer prognosis and
diagnosis. The analysis reviews technological developments, product innovations and recent strategic
industry activity of major players across different product categories. It analyzes their strengths and
weaknesses, opportunities and threats facing various devices and drugs in this market space and
developments already on the market. It discusses the major issues involved in the research and
development (R&D) of more effective devices for drug delivery to the lungs, along with new products in


According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with
breast cancer annually. It is no longer necessary for one breast cancer treatment to fit all cases, a
concept that should be welcome news for physicians and their patients alike. Personalized medicine is
relatively new to the market research report format, and it provides business tools to evaluate new
commercial opportunities in diagnostics and biomarker fields. The scope of this report covers global
companies developing tests relevant for breast cancer prognosis and diagnosis. This study describes
current products in each area, identifies current market participants, and most importantly, notes the
trends that will affect further product development in this area.

Companion diagnostics is also a part of the personalized medicine revolution. The field evolved as a
continuation of biomarker studies and diagnostics testing. The breast cancer predictive testing segment
of the industry is still growing; it has a number of successful FDA–approved products. This study will
provide knowledge of the current state of the companion diagnostics industry and the new technologies
in assay development. More importantly, it will describe potential and novel commercial developments
in this area. The report will also provide an overview covering major biotechnology and pharma
companies involved in developing innovative, targeted breast cancer treatments that address major
unmet medical needs to advance cancer care. In addition, the report also provides information
regarding the less-developed sectors of this market and presents a list of current companies that have
new predictive testing products and drugs in development for breast cancer.

Get your copy of this report @

Report Details:
Published: June 2012
No. of Pages: 166
Price: Single User License: US$ 4850 Corporate User License: US$8500


This report will provide an update and on overview on predictive testing in breast cancer diagnostics and
drug technologies and global markets. The study’s objective is to review the tumor marker-based
predictive companion tests and drugs for breast cancer, and then assess their global growth potential
over a five-year period from 2011 to 2016. Review includes global markets for breast cancer incidence,
current drugs, new developments, predictive diagnostic tests, market trends and new technologies, and
developments and forecast trends for the use of current tests for better diagnosis and prognosis for
breast cancer through 2016. Important tests, technologies and developments; market share by drug,
test, current products on the market and market share by company or product; and statistical
information for types of breast cancer prevalence globally, with special emphasis on the U.S. market, are
discussed. The report focuses on tumor marker-based testing that provides vital information about the
cancer. These tests can help determine the appropriate medicine and timing of treatment to address the
disease most effectively. The report also includes current issues and trends affecting the industry. The
report covers products in development, new technologies, trends, alliances, patents and mergers. It
offers market data with respect to segments and geography. Other breast cancer detection and
screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this


This report is an exhaustive study on the global breast cancer market, giving crucial statistics and
analysis on existing drugs, diagnostic technologies, latest trends, market structure, market size, key drug
segments, important trends in technology development, major opportunities and market shares of key
players and drugs. This information may prove crucial for the firms or investors seeking opportunities in
the concerned sector. This report shows tests currently being used for breast cancer diagnosis and
prognosis, new developments, spending trends and revenue prospects for these technologies. It
provides market data for 2010 to 2016, and also covers commercial prospects for breast cancer
diagnostic and prognostic assays.


Both primary and secondary research methodologies were used in preparing this report. Secondary
sources include books, newspapers, trade journals, white papers, industry portals, government
agencies, trade associations, industry news, and paid and free databases. The base year of the report is
2010, with forecast data provided through 2016. Historical, base year and forecast data are provided for
each market segment of this report.

The report provides a comprehensive review of breast cancer incidence, development of the disease,
drugs currently used and diagnostic technologies based on tumor markers for accurate diagnosis and aid
in deciding treatment plans for patients. The new analysis reviews technological developments, product
innovations and introductions, and recent strategic industry activity of major players across various
product categories. Growth rates, global incidence and projections are determined through a
compilation of data, including past trends, future trends, demographics, incidence, mortality, products
in R&D and current product growth. A comprehensive and exhaustive search of the literature on breast
cancer assay development and already–marketed products, breast cancer global incidence and latest
drug developments was conducted. These secondary sources included scientific-related journals and
articles, textbooks, press releases, marketing literature, other product or promotional literature, annual
reports and security analyst reports. Patent searches and analyses were also conducted. Some informal
interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical
companies. Other resources included academic, technology transfer offices and consulting companies.


Usha Nagavarapu is a pharmaceutical professional with experience in scientific and alliance
development. This includes more than 10 years of drug and device product development and alliance
management experience. She has managed preclinical discovery programs from target identification
through design of Phase I testing, including IND enabling studies, and assisted out-licensing and portfolio
development activities. Strong focus areas include oncology, dermatology and cardiovascular diseases.
She has extensive experience working with early-start-ups to fulfill operational obligations while
minimizing overall operational cost and burden.


BCC Research offers an online information retrieval service. Its home page, located at, enables readers to:
Examine the complete BCC Research catalog of market research reports and place direct orders.
Subscribe to any of BCC Research’s many industry newsletters.
Read announcements of recently published reports and newly launched newsletters.
Register for its well-known conferences.
Request additional information on any BCC research product.
Take advantage of special offers.


The information developed in this report is intended to be as reliable as possible at the time of
publication and of a professional nature. This information does not constitute managerial, legal or
accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement
of any product, as much of the information is of a speculative in nature. The author assumes no
responsibility for any loss or damage that might result from reliance on the reported information or
from its use.

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441

Connect With Us:

To top